A review of the literature for whole-body FDG PET in the management of patients with melanoma

Quarterly Journal of Nuclear Medicine

Volumn 44, Issue 2, 2000, Pages 153-167

  Schwimmer, J ^a   Essner, R ^a   Patel, A ^a   Jahan, S A ^a   Shepherd, J E ^a   Park, K ^a   Phelps, M E ^a   Czernin, J ^a   Gambhir, S S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fludeoxy glucose F18; Melanoma secondary; Neoplasm recurrence, local; Tomography, emission computed

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER STAGING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DOCUMENT EXAMINATION; HEALTH CARE UTILIZATION; HUMAN; MEDICAL DOCUMENTATION; MELANOMA; META ANALYSIS; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; REVIEW; TUMOR RECURRENCE; WHOLE BODY TOMOGRAPHY;

CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FLUORODEOXYGLUCOSE F18; HUMANS; MELANOMA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PEER REVIEW, RESEARCH; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE-BODY IRRADIATION;

EID: 0033869181     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Current concepts review: Management of melanoma
2. Cancer statistics, 1999
3. The incidence of malignant melanoma in the United States: Issues as we approach the 21st century
4. Sorting the hype from the facts in melanoma
5. Sunburn, sunscreen, and melanoma
6. An inquiry into the epidemiology of melanoma
7. Rising trends in melanoma: A hypothesis concerning sunscreen effectiveness
8. The prevalence of cancer. Estimates based on the Connecticut Tumor Registry
9. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II)
10. Recent advances in the care of the patient with malignant melanoma
11. Effectiveness of positron emission tomography for the detection of melanoma metastases
12. Positron emission tomography in the detection and management of metastatic melanoma
13. The role of surgery in the treatment of nonregionally recurrent melanoma
14. Metastasectomy in malignant melanoma
15. An estimate of the annual direct cost of treating cutaneous melanoma
16. (68Ga)-EDTA positron emission tomography in the diagnosis of brain tumors
17. Correlation between initial and long-term responses of spontaneous pet animal tumors to heat and radiation or radiation alone
18. Analysis of prognostic variables which influence early and long-term response of pet animal tumors to radiation alone and radiation plus heat
19. Tumor localization of alpha-aminoisobutyric acid (AIB) in human melanoma heterotransplants
20. Tumor localization of the metabolically trapped radiolabeled substrates 2-deoxy-D-glucose and aminocyclopentanecarboxylic acid in human melanoma heterotransplants
21. Potential radiopharmaceuticals for the detection of ocular melanoma. Part III. A study with 14C and 11C labelled tyrosine and dihydroxyphenylalanine
22. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma
23. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose
24. High accumulation of 2-deoxy-2-fluorine-18-fluoro-D-galactose by well-differentiated hepatomas of mice and rats
25. The assessment of tumor blood flow factors using dynamic CT - A comparison with positron emission tomography
26. High-resolution positron emission tomography of human ovarian cancer in nude rats using 124I-labeled monoclonal antibodies
27. Contributions of nuclear medicine to the therapy of malignant tumors
28. Quantification of glucose utilization in liver metastases: Parametric imaging of FDG uptake with PET
29. A unique in vivo assessment of 4-[10B]borono-L-phenylalanine in tumour tissues for boron neutron capture therapy of malignant melanomas using positron emission tomography and 4-borono-2-[18F]fluoro-L-phenylalanine
30. 67Ga-9N3 uptake by xenografts of human melanotic melanoma in mice
31. Establishment and characterization of monoclonal antibodies against an octahedral gallium chelate suitable for immunoscintigraphy with PET
32. 4-Borono-2-[18F]fluoro-D,L-phenylalanine: A possible tracer for melanoma diagnosis with PET
33. MRI, antibody-guided scintigraphy, and glucose metabolism in uveal melanoma
34. Feasibility of estimating the temperature distribution in a tumor heated by a waveguide applicator
35. [14C]deoxyglucose uptake and imaging in malignant melanoma
36. Early changes in tumor metabolism after treatment: The effects of stereotactic radiotherapy
37. The applications of PET in clinical oncology
38. Radioimmunology. Imaging and therapy
39. Spontaneous tumors in dogs and cats: Models for the study of cancer biology and treatment
40. Muscle uptake of 18FDG in positron emission tomography
41. Clinical use of PET
42. Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma
43. Lymphatic drainage from the skin of the back to retroperitoneal and paravertebral lymph nodes in melanoma patients
44. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma
45. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients
46. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning
47. Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anti-cancer prodrug activation
48. Radioiodine-labelled alpha-methyl-tyrosine in malignant melanoma: Cell culture studies and results in patients
49. In vivo diagnosis of human malignant melanoma with positron emission tomography using specific melanoma-seeking 18F-DOPA analogue
50. PET in oncology: Willit replace the other modalities?
51. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma
52. In vivo evaluation of [18F]1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine: A selective sigma-1 receptor radioligand for PET
53. Glucose metabolism and pathological findings in uveal melanoma: Preliminary results
54. Normal thymic uptake of FDG on PET imaging
55. Optimized sampling and parameter estimation for quantification in whole body PET
56. Cost-effectiveness of PET imaging in clinical oncology
57. Biological activity of 26-succinylbryostatin 1
58. Synthesis of [11C-methyl]-alpha-aminoisobutyric acid (AIB)
59. Clinical value of positron emission tomography (PET) in oncologic questions: Results of an interdisciplinary consensus conference
60. Functional role of sialyl Lewis X and fibronectin-derived RGDS peptide analogue on tumor-cell arrest in lungs followed by extravasation
61. Whole-body PET: Physiological and artifactual fluorodeoxyglucose accumulations
62. Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells
63. Quantification of serial tumor glucose metabolism
64. FDG-PET screening for cerebral metastases in patients with suspected malignancy
65. Lack of expression of dopamine D2 receptors in malignant melanoma: Evidence for interaction of iodobenzofurans with melanin
66. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma
67. Carbon-11-methionine PET imaging of malignant melanoma
68. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia
69. Malignant melanoma: Staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose
70. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines
71. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose
72. Naturally occurring tumors in dogs as comparative models for cancer therapy research
73. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy
74. 18-Fluorodeoxyglucose imaging in oncology
75. Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: Validation by whole body FDG-PET and conventional diagnostics
76. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients
77. Progress of nuclear oncology
78. Relevance of positron emission tomography (PET) in oncology
79. Correlation of CT-guided fine-needle aspiration biopsy of the liver with fluoride-18 fluorode-oxyglucose positron emission tomography in the assessment of metastatic hepatic abnormalities
80. FDG PET-negative liver metastases of a malignant melanoma and FDG PET-positive hurthle cell tumor of the thyroid
81. False-negative FDG PET imaging in a patient with metastatic melanoma and ileal intus-susception
82. Quality criteria for cost-benefit analysis in oncologic nuclear medicine and state of its realization
83. Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: A comparison of ultrasonographic and radiological methods of diagnosis
84. Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer, lymphoma and melanoma
85. Tracers for imaging melanin with positron emission tomography
86. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer
87. Brain tumor evaluation using Rb-82 and positron emission tomography
88. Evaluation of blood-brain barrier permeability changes in rhesus monkeys and man using 82Rb and positron emission tomography
89. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography
90. Metabolic imaging of uveal melanoma using positron emission tomography
91. How platelet aggregation affects B16BL6 melanoma cell trafficking
92. Malignant melanoma staging using whole-body positron emission tomography
93. Right atrial metastatic melanoma in a patient with transient ischemic attacks
94. Malignant mucosal melanoma of the head and neck: Review of the literature and report of 14 patients
95. Tumor cells with organ-specific metastatic ability show distinctive trafficking in vivo: Analyses by positron emission tomography and bioimaging
96. 123I-alpha-methyltyrosine scintigraphy in malignant melanoma
97. Early detection of melanoma metastasis using fludeoxyglucose F18 positron emission tomography
98. Whole-body positron emission tomography: An accurate staging modality for metastatic melanoma
99. Detection of unsuspected metastasis in a melanoma patient with positron emission tomography
100. Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors
101. Current therapy for cutaneous melanoma
102. Follow-up of patients with a thin melanoma
103. Blue cross and blue shield association initiatives in technology assessment
104. Kaiser permanente's new technology committee: Coverage decisionmaking in a group model health maintenance organization
105. Decisionmaking in the health care finance administration
106. Malignant melanoma: A clinical review
107. Pitfalls in oncologic diagnosis with FDG PET imaging: Physiologic and benign variants
108. Skin cancer prevention and screning: Summary of the American College of Preventive Medicine's practice policy statements
109. Melanoma's toll is on the rise
110. Estimating diagnostic accuracy from multiple conflicting reports: A new meta-analytic method